Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ursula A Matulonis

Showing results (41-50 of 236) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2016
Biomarkers of Response and Resistance to DNA Repair Targeted TherapiesElizabeth H Stover, Panagiotis A Konstantinopoulos, Ursula A Matulonis, et al.
Gynecologic Oncology|March 21, 2025
Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancersElizabeth K Lee, David L Kolin, Ursula A Matulonis, et al.
Cancer|October 23, 2014
Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trialsUrsula A Matulonis, Amit M Oza, Tony W Ho, et al.
Cancer Nursing|October 23, 2012
Hopelessness and complementary therapy use in patients with ovarian cancerAnne H Gross, Jerry Cromwell, Marsha Fonteyn, et al.
Gynecologic Oncology|October 5, 2020
Clinical assays for assessment of homologous recombination DNA repair deficiencyElizabeth H Stover, Katherine Fuh, Panagiotis A Konstantinopoulos, et al.
Expert Opinion on Investigational Drugs|February 23, 2016
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancerS Percy Ivy, Joyce F Liu, Jung-Min Lee, et al.
Gynecologic Oncology|August 20, 2013
Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patientsJoyce F Liu, David Kindelberger, Courtney Doyle, et al.
Gynecologic Oncology|February 28, 2012
Bevacizumab rechallenge after first line maintenance bevacizumabPanagiotis A Konstantinopoulos, Suzanne T Berlin, Susana M Campos, et al.
Nature Reviews. Disease Primers|August 26, 2016
Ovarian cancerUrsula A Matulonis, Anil K Sood, Lesley Fallowfield, et al.
International Journal of Cancer|November 7, 2019
Prediagnosis and postdiagnosis smoking and survival following diagnosis with ovarian cancerTianyi Wang, Mary K Townsend, Vani Simmons, et al.
Pageof 24

Showing results (41-50 of 236) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2016
Biomarkers of Response and Resistance to DNA Repair Targeted TherapiesElizabeth H Stover, Panagiotis A Konstantinopoulos, Ursula A Matulonis, et al.
Gynecologic Oncology|March 21, 2025
Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancersElizabeth K Lee, David L Kolin, Ursula A Matulonis, et al.
Cancer|October 23, 2014
Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trialsUrsula A Matulonis, Amit M Oza, Tony W Ho, et al.
Cancer Nursing|October 23, 2012
Hopelessness and complementary therapy use in patients with ovarian cancerAnne H Gross, Jerry Cromwell, Marsha Fonteyn, et al.
Gynecologic Oncology|October 5, 2020
Clinical assays for assessment of homologous recombination DNA repair deficiencyElizabeth H Stover, Katherine Fuh, Panagiotis A Konstantinopoulos, et al.
Expert Opinion on Investigational Drugs|February 23, 2016
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancerS Percy Ivy, Joyce F Liu, Jung-Min Lee, et al.
Gynecologic Oncology|August 20, 2013
Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patientsJoyce F Liu, David Kindelberger, Courtney Doyle, et al.
Gynecologic Oncology|February 28, 2012
Bevacizumab rechallenge after first line maintenance bevacizumabPanagiotis A Konstantinopoulos, Suzanne T Berlin, Susana M Campos, et al.
Nature Reviews. Disease Primers|August 26, 2016
Ovarian cancerUrsula A Matulonis, Anil K Sood, Lesley Fallowfield, et al.
International Journal of Cancer|November 7, 2019
Prediagnosis and postdiagnosis smoking and survival following diagnosis with ovarian cancerTianyi Wang, Mary K Townsend, Vani Simmons, et al.
Pageof 24